Tofacitinib Citrate is Used for treating moderate to severe ulcerative colitis and rheumatoid arthritis. It was first introduced by Pf Prism Cv in its drug Xeljanz on Nov 6, 2012. Another drug containing Tofacitinib Citrate is Xeljanz Xr. 7 different companies have introduced drugs containing Tofacitinib Citrate.

Tofacitinib Citrate Patents

Given below is the list of patents protecting Tofacitinib Citrate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Xeljanz	US6956041	Pyrrolo[2,3-d]pyrimidine compounds	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	US6965027	Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate	Mar 25, 2023 (Expired)	Pf Prism Cv
Xeljanz	US6965027	Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate	Mar 25, 2023 (Expired)	Pf Prism Cv
Xeljanz	US7091208	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	US7265221	Pyrrolo[2,3-d]pyrimidine compounds	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	US7265221	Pyrrolo[2,3-d]pyrimidine compounds	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	US7301023	Chiral salt resolution	May 23, 2022 (Expired)	Pf Prism Cv
Xeljanz	US7301023	Chiral salt resolution	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	US7842699	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2020 (Expired)	Pf Prism Cv
Xeljanz	USRE41783	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2025	Pfizer
Xeljanz	USRE41783	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2025	Pf Prism Cv
Xeljanz Xr	US10639309	Tofacitinib oral sustained release dosage forms	Mar 14, 2034	Pfizer
Xeljanz Xr	US11253523	Tofacitinib oral sustained release dosage forms	Mar 14, 2034	Pfizer
Xeljanz Xr	US6956027	N-terminally chemically modified protein compositions and methods	Mar 25, 2023 (Expired)	Pfizer
Xeljanz Xr	US6956041	Pyrrolo[2,3-d]pyrimidine compounds	Dec 08, 2020 (Expired)	Pfizer
Xeljanz Xr	US6965027	Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate	Mar 25, 2023 (Expired)	Pfizer
Xeljanz Xr	US7091208	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2020 (Expired)	Pfizer
Xeljanz Xr	US7265221	Pyrrolo[2,3-d]pyrimidine compounds	Dec 08, 2020 (Expired)	Pfizer
Xeljanz Xr	US7301023	Chiral salt resolution	Dec 08, 2020 (Expired)	Pfizer
Xeljanz Xr	US7842699	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2020 (Expired)	Pfizer
Xeljanz Xr	US9937181	Tofacitinib oral sustained release dosage forms	Mar 14, 2034	Pfizer
Xeljanz Xr	USRE41783	Pyrrolo[2,3-D]pyrimidine compounds	Dec 08, 2025	Pfizer

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tofacitinib Citrate's patents.

Latest Legal Activities on Tofacitinib Citrate's Patents

Given below is the list recent legal activities going on the following patents of Tofacitinib Citrate.

Event	Date	Patent/Publication
Today's Critical Events
Payment of Maintenance Fee, 4th Year, Large Entity	12 Oct, 2023	US10639309
Expire Patent	02 Jan, 2023	US7842699
Maintenance Fee Reminder Mailed	18 Jul, 2022	US7842699
Recordation of Patent Grant Mailed	22 Feb, 2022	US11253523
Patent Issue Date Used in PTA Calculation	22 Feb, 2022	US11253523
Email Notification	03 Feb, 2022	US11253523
Issue Notification Mailed	02 Feb, 2022	US11253523
Mailing Corrected Notice of Allowability	27 Jan, 2022	US11253523
Email Notification	27 Jan, 2022	US11253523
Dispatch to FDC	25 Jan, 2022	US11253523

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳